The ELCC 2023 programme is now online!
- Update your knowledge in the early detection of thoracic malignancies
- Review the current state-of-the-art systemic management of lung cancer
- Learn how to best sequence or combine multimodal therapies in common and rare thoracic tumours
- Review the emerging contribution of precision medicine, omics technologies and artificial intelligence in the optimal management of patients with cancers of the thorax
ESMO-MORA: The Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.